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Abstract. Methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien28-oate (CDDO-Me) has shown potent antitumorigenic
activity against a wide range of cancer cell lines in vitro and
inhibited the growth of liver, lung and prostate cancer in vivo.
In the present study, we examined the antitumor activity of
CDDO-Me for pancreatic ductal adenocarcinoma (PDAC)
cells with and without activating K-ras mutations. Treatment
of K-ras mutant MiaPaCa-2 and K-ras normal BxPC-3 cells
with CDDO-Me elicited strong antiproliferative and proapoptopic responses in both cell lines in culture. The inhibition of
cell proliferation and induction of apoptosis was accompanied
by the inhibition of antiapoptotic/prosurvival p-Akt, NF-кB
and p-mTOR signaling proteins. For testing efficacy of
CDDO-Me in vivo heterotopic and orthotopic xenografts were
generated by implanting BxPC-3 and MiaPaCa-2 cells subcutaneously and in the pancreatic tail, respectively. Treatment
with CDDO-Me significantly inhibited the growth of BxPC-3
xenografts and reduced the levels of p-Akt and p-mTOR in
tumor tissue. In mice with orthotopic MiaPaCa-2 xenografts,
treatment with CDDO-Me prolonged the survival of mice
when administered following the surgical resection of tumors.
The latter was attributed to the eradication of residual PDAC
remaining after resection of tumors. These preclinical data
demonstrate the potential of CDDO-Me for treating primary
PDAC tumors and for preventing relapse/recurrence through
the destruction of residual disease.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) accounts for >90%
of all exocrine pancreatic cancers and is almost uniformly
lethal with an estimated annual number of 45,220 new cases
~38,460 annual deaths and a 5-year survival rate of <5% (1-3).
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Late initial diagnosis, aggressive metastatic behavior and resistance to chemo-radiotherapy render pancreatic cancer one of
the most difficult to treat of all malignancies. Systemic chemotherapy with either gemcitabine or FOLFIRINOX (5-FU,
irinotecan and oxaliplatin) is the current standard of care for
advanced PDAC, providing short-term symptomatic improvement with minor impact on survival (4-6). Surgical resection
is potentially curative; however, nearly 80% of the patients are
diagnosed with locally advanced disease, precluding surgical
intervention. Even in early stage PDAC patients in whom
cancerous tissue is surgically resected (Whipple procedure), a
majority of them relapse within two years after surgery. Thus,
there is a tremendous need for novel therapeutics and treatment strategies for treating primary and residual PDAC for
preventing relapse after pancreatic cancer surgery.
Aberration of apoptosis has been implicated in carcinogenesis and resistance to conventional anticancer therapies
(7). Thus, promotion of apoptosis in cancer cells with novel
agents could lead to tumor regression and improved prognosis.
Triterpenes or triterpenoids are members of a large family of
structurally related compounds known as cyclosqualenoids
that are widely distributed in nature (8). Oleanolic acid is naturally occurring triterpenoid that has been used in traditional
medicine as an anticancer and anti-inflammatory agent (9-11).
In order to increase the anti-inflammatory and anticancer
activity of oleanolic acid several synthetic analogues have
been synthesized. Synthetic lealane triterpenoid 2-cyano-3,12dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its C-28
methyl ester derivative methyl-2-cyano-3,12-dioxooleana1,9(11)-dien-28-oate (CDDO-Me) and C-28 imidazole
derivative 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole (CDDO-Im) exhibit stronger anti-inflammatory activity
than oleanolic acid (12,13). CDDOs have also shown potent
antiproliferative and proapoptotic activity in diverse types of
tumor cell lines through the inhibition of MAPK (Erk1/2),
NF-κ B and PPARγ signaling pathways and they induce cytoprotective phase 2 response through Nrf2 signaling (14-20). In
previous studies, we have demonstrated that the antiproliferative and apoptosis inducing activity of CDDO-Me in prostate
cancer cell lines is mediated through the inhibition of antiapoptotic (prosurvival) Akt/NF-κ B/mTOR signaling pathways
(21). Although the antiproliferative activity of CDDOs in
PDAC cell lines in vitro has been reported their therapeutic
efficacy for PDAC in vivo has not been adequately studied.
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We have investigated the therapeutic efficacy of CDDO-Me
against heterotopic and orthotopic tumor xenografts generated
with human PDAC cell lines with a focus on preventing or
delaying relapse/recurrence. Our data show therapeutic efficacy of CDDO-Me in treating primary tumor growth as well
as in preventing/delaying recurrence of PDAC when administered after surgical removal of tumors.
Materials and methods
Reagents. CDDO-Me was obtained from the National Cancer
Institute, Bethesda, MD, USA through the Rapid Access to
Intervention Development Program. Antibodies against p-Akt
(ser473), p-mTOR (Ser2448), PARP-1 and β-actin were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
CellTiter 96 AQueous One Solution Proliferation assay system
was from Promega (Madison, WI, USA) and Annexin V-FITC
apoptosis detection kit II was obtained from BD Pharmingen
(San Diego, CA, USA).
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14,000 x g for 10 min at 4˚C and protein concentrations were
determined. Samples (50 µg) were boiled in an equal volume
of sample buffer [20% glycerol, 4% SDS, 0.2% bromophenol
blue, 125 mM Tris-HCl (pH 7.5), and 640 mM 2-ME] and
separated on pre-casted Tris-glycine polyacrylamide gels
using the XCell Surelock™ Mini-Cell, in Tris-glycine SDS
running buffer, all from Novex (Invitrogen, Carlsbad, CA,
USA). Proteins resolved on the gels were transferred to PVDF
membranes. Membranes were blocked with 5% milk in 10 mM
Tris-HCl (pH 8.0), 150 mM NaCl with 0.05% Tween-20
(TPBS) and probed using specific antibodies against proteins
of interest or β-actin (loading control) and HRP-conjugated
secondary antibody. Immune complexes were visualized with
enhanced chemiluminescence. Protein bands were imaged and
band densities analyzed using the NIH/Scion image analysis
software. The protein band densities were normalized to the
corresponding β-actin band densities and percent change in
signal strength was calculated.

Mice. Six-week-old female Scid/Ncr mice were purchased
from the Charles River Laboratories, Inc., Frederic, MD,
USA. Mice were maintained in a temperature-controlled room
(68-72˚F) with a 12-h light/dark cycle and provided semi-purified AIN-76A mouse chow and water ad libitum. Mice were
acclimated for one week before starting the experiment. All
animal treatments were according to the protocol approved by
the Institutional Animal Care and Use Committee (IACUC).

Generation of tumor xenografts. Heterotopic PDAC xenografts were generated by implanting 1x106 BxPC-3 cells in
50 µl of PBS subcutaneously in the right flank of 7-week-old
Scid-Ncr female mice. Cells were allowed to form tumors for
7 days before initiating treatment with CDDO-Me. Orthotopic
PDAC xenografts were generated by implanting MiaPaCa-2
cells stably expressing luciferase gene (MiaPaCa-2-Luc cells)
in the pancreatic tail of Scid/Ncr mice. Briefly, mice were
anesthetized with ketamine/xylazine (100/8 mg/kg i.p.) and
a 2-cm long subcostal laparotomy was performed after clipping hair. Pancreas were exposed and 1x106 MiaPaCa-2-Luc
cells in 20 µl of PBS were injected in the pancreatic tail with a
30 G needle. Proper deposition of cells was confirmed by bleb
formation at the site of injection. The fascia and skin incisions
were sutured following implantation of tumor cells.

Measurement of cell viability. Tumor cells (1x10 4) were
seeded into each well of a 96-well plate in 100 µl of tissue
culture medium. After incubation at 37˚C in a humidified
atmosphere consisting of 5% CO2 and 95% air for 24 h, cells
were treated with CDDO-Me at concentrations of 0.625-5 µM
for 72 h. Cell viability was then determined by the MTS assay
using CellTiter 96® AQueous One Solution Proliferation assay
system.

Residual disease. To generate residual disease, 1x106 MiaPaCa2-Luc cells in 20 µl of PBS were injected in the pancreatic tail
as described above. Cells were first allowed to form tumors
for 28 days and then mice were anesthetized with ketamine/
xylazine (100/8 mg/kg i.p.) and partial pancreatectomy was
performed to remove all visible tumor growth. After resection
of tumors, incisions were sutured and mice were either treated
or not with CDDO-Me.

Measurement of apoptosis. Apoptosis was assessed by the
binding of Annexin V-FITC to phosphotidylserine, which
is externalized to the outer leaflet of the plasma membrane
early during induction of apoptosis. Briefly, untreated cells
and cells treated with CDDO-Me for 24 h were resuspended
in the binding buffer provided in the Annexin V-FITC apoptosis detection kit and reacted with 5 µl of Annexin V-FITC
reagent and 5 µl of propidium iodide (PI) for 30 min at
room temperature in the dark. Stained cells were analyzed
by flow cytometry using Accuri C6 flow cytometer (Accuri
Cytometers Inc. Ann Arbor, MI, USA). The induction of
apoptosis by CDDO-Me was confirmed by the cleavage of
PARP-1 by western blotting.

Treatment with CDDO-Me. Two treatment paradigms were
followed. To treat primary tumor growth, treatment was started
on day 7 after implantation of BxPC-3 cells subcutaneously.
To treat residual disease, treatment was started one day after
resection of tumors on day 28 after implantation of MiaPaCa2-Luc cells in the pancreas. Mice in both treatment paradigms
were administered CDDO-Me at a dose of 15 µmol/kg
(7.5 mg/kg), 5 days a week in 0.1 ml of vehicle consisting of
cremophor-EL:DMSO:PBS (1:1:8) by oral gavage until day 40
(heterotopic xenografts) to treat primary tumor growth or day
100 (orthotopic xenografts) to treat residual disease. Control
mice were treated with vehicle alone without CDDO-Me.

Cell culture. Human PDAC cell lines MiaPaCa-2 and BxPC-3
were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). Cell lines were cultured at
37˚C in a humidified atmosphere consisting of 5% CO2 and
95% air and maintained by subculturing cells twice a week.

Western blotting. Cell lysates were prepared using NP 40
cell lysis buffer. Lysates were clarified by centrifugation at

Bioluminecsent imaging (BLI). The growth progression
of orthotopic PDAC xenografts generated by implanting
MiaPaCa-2-Luc cells in the pancreas was measured
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Figure 1. CDDO-Me inhibits the proliferation of PDAC cells. MiaPaCa-2 or BxPC-3 cells (1x104) in 100 µl of culture medium were seeded in each well of a
96-well microtiter plate and allowed to adhere for 24 h. Cells were treated with CDDO-Me at concentrations ranging from 0 to 5 µM for 72 h in triplicate. Cell
viability was measured by MTS assay using CellTiter AQueous assay system from Promega. Data are presented as percent reduction in viability obtained in
three independent experiments. *p≤0.05 compared to control cells (no CDDO-Me).

non-invasively by BLI imaging using Kodak Multispectral
Imaging system (Carestream Health, Woodbridge, CT, USA).
Briefly, mice were anesthetized with isofluorane and anesthesia
was maintained by inhalation of a mixture of isofluorane (2%)
and oxygen during the imaging procedure. First an X-ray
image was taken and then BLI was obtained for 2 min, 10 min
after i.p. injection of sodium luciferin (150 mg/kg). The X-ray
and BLI images were overlaid and peak photon flux (photon/
sec/mm2) from the tumors was plotted against time to obtain
tumor growth curve.
Statistical analysis. Most data are presented as means ± SD
and outcomes for treated and untreated cells were compared
by Student's t-test. Differences were considered significant at
p<0.05.
Results
CDDO-Me inhibits proliferation and induces apoptosis in
PDAC cells. To test the effect of CDDO-Me on the proliferation of PDAC cells, 1x104 MiaPaCa-2 or BxPC-3 cells were
plated in 96-well microtiter plates for 24 h and then treated with
CDDO-Me for 72 h at concentrations ranging from 0 to 5 µM.
Viability of cultures was assessed by MTS assay and percent
reduction in viability of cultures was determined. As shown in
Fig. 1, significant decrease in the viability of cell cultures was
observed in both cell lines treated with CDDO-Me at concentrations of 1.25-5 µM (MiaPaCa-2: 44-73%; BxPC-3: 57-79%).
To determine whether inhibition of proliferation of
PDAC cells by CDDO-Me was associated with induction of
apoptosis, binding of Annexin V-FITC to cells treated with
CDDO-Me was measured. For this, MiaPaCa-2 or BxPC-3
cells were treated or not with CDDO-Me (0-5 µM) for 24 h
and analyzed for Annexin V-FITC binding by flow cytometry.
As shown in Fig. 2A, the percentage of Annexin V-FITC
binding MiaPaCa-2 cells increased from <2% (untreated cells)
to 17, 24, 37 and 62% following treatment with CDDO-Me
at 0.625, 1.25, 2.5 and 5 µM, respectively. The percentage of
Annexin V-FITC binding BxPC-3 cells was 1, 9, 16, 56 and
67% at 0, 0.625, 1.25, 2.5 and 5 µM CDDO-Me.

Figure 2. CDDO-Me induces apoptosis in PDAC cells. (A) Binding of
Annexin V-FITC. MiaPaCa-2 cells and BxPC-3 cells were treated with
CDDO-Me at concentrations of 0-5 µM for 24 h. Cells were then reacted
with 5 µl of Annexin V-FITC and 5 µl PI for 30 min at room temperature
in the dark. The percentage of Annexin V-FITC-positive tumor cells was
determined by flow cytometry. (B) Cleavage of PARP-1. MiaPaCa-2 cells and
BxPC-3 cells were treated with CDDO-Me (0-5 µM) for 24 h. Cell lysates
were analyzed for cleavage of PARP-1 by western blotting. Experiment was
repeated twice.
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Figure 3. CDDO-Me downregulates prosurvival signaling proteins in PDAC cells. MiaPaCa-2 and BxPC-3 cells were treated with CDDO-Me (0-5.0 µM) for
24 h. Levels of p-Akt, NF-κ B (p65), p-mTOR, and β-actin (loading control) were analyzed by western blotting. Experiment was repeated two times.

anti-apoptotic (prosurvival) signaling proteins that are
constitutively active in a variety of human cancers, providing
survival advantage to cancer cells. We investigated whether
PDAC cells express constitutively active Akt (p-Akt) and
mTOR (p-mTOR) and the effect CDDO-Me has on the
expression of these signaling proteins. Cell lysates were
prepared from MiaPaCa-2 and BxPC-3 cells treated or not
with CDDO-Me (0-5 µM) for 24 h and analyzed by western
blotting for the levels of these proteins. Fig. 3 shows that both
PDAC cell lines expressed p-Akt, NF-кB and p-mTOR and
treatment with CDDO-Me significantly or completely inhibited their expression at concentrations of 1.25-5 µM. These
data demonstrated that induction of apoptosis by CDDO-Me
is attributable at least in part to the inhibition of anti-apoptotic
Akt, NF-κ B and mTOR.

Figure 4. CDDO-Me inhibits growth of PDAC xenografts and expression of
prosurvival signaling proteins in tumor tissue. (A) BxPC-3 cells (1x106) in
50 µl of PBS were injected in the flank of seven-week-old female Scid/Ncr
mice. Starting on day 7 after implantation of tumor cells mice were treated
with CDDO-Me at a dose of 15 µmol/kg by oral gavage as described in
Materials and methods. Control mice were treated with vehicle alone without
CDDO-Me. Tumor dimensions (length and width) were measured with a
caliper at weekly intervals. Data are plotted as tumor volumes vs days past
tumor cell implantation ± SD. (B) At termination of the experiment (day 40),
tumor tissue from control and CDDO-Me treated mice was harvested and
levels of p-Akt and p-mTOR were analyzed by western blotting.

The induction of apoptosis by CDDO-Me was confirmed
by the cleavage of native PARP-1. As shown in Fig. 2B, treatment with CDDO-Me caused the emergence of 89 kDa cleaved
PARP-1 fragment in both cell lines. Together, increase in
binding of Annexin V-FITC and cleavage of PARP-1 demonstrated induction of apoptosis by CDDO-Me in PDAC cells.
CDDO-Me inhibits p-Akt, NF-кB and p-mTOR signaling
proteins in PDAC cells. Akt, NF-кB and mTOR are

CDDO-Me inhibits the growth of BxPC-3 xenografts. Next we
determined the tumor inhibitory activity of CDDO-Me in vivo
against hetrotopic BxPC-3 xenografts. One week after injection of 1x106 BxPC-3 PDAC cells in the flanks of Scid-Ncr
mice, mice were treated with CDDO-Me (15 µmol/kg) or
vehicle only by oral gavage, 5 days/week for 5 weeks (n=5) and
experiment was terminated on day 40. To measure the effect
of CDDO-Me on progression of tumor growth, tumor dimentions (length and width) were measured by a caliper and tumor
volume was calculated by the formula: (length x width2)/2.
As shown in Fig. 4A, treatment with CDDO-Me significantly
inhibited the growth of BxPC-3 xenografts compared to
vehicle contol animals [tumor volume (mm3 ± SD): control,
53±10, 98±23, 226±21 and 284±39; CDDO-Me, 22±6, 37±10,
79±16 and 111±19 on days 14, 21, 28 and 35 after implantation
of tumor cells]. Furthermore, treatment with CDDO-Me also
reduced p-Akt and p-mTOR levels in the tumor tissue (76 and
54% reduction, respectively) (Fig. 4B). These data demonstrated therapeutic efficacy of CDDO-Me against PDAC
in vivo and provided evidence that activated Akt and mTOR
are therapeutic targets of CDDO-Me in PDAC tumors.
Generation of orthotopic PDAC xenografts and efficacy of
CDDO-Me for residual disease. To closely mimic physiological microenvironment of PDAC in patients for treatment with
CDDO-Me we generated orthotopic xenografts by injecting
MiaPaCa-2-Luc cells in the pancreatic tail in Scid/Ncr mice.
The development and progression of orthotopic xenografts
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Figure 5. Bioluminescent imaging of orthotopic PDAC xenografts and efficacy of CDDO-Me in preventing recurrence. Female Scid/Ncr mice were injected
with 1x106 MiaPaCa-2 cells stably expressing luciferase gene (MiaPaCa-2-Luc cells) in the pancreatic tail. The growth of xenografts was monitored by
non-invasive bioluminescent imaging (A and B) and a growth curve was generated by plotting BLI signals from tumors (photon emission/sec/mm 2) vs time
(days) after implantation of MiaPaCa-2-Luc cells (C). Size and histology of a tumor harvested on day 35 is also shown (D and E). (F) To determine efficacy
of CDDO-Me for preventing relapse, all visible tumor growth was resected on day 28 after implantation of MiaPaCa-2-Luc cells and mice were treated with
CDDO-Me at a dose of 15 µmol/kg orally, 5 days a week until day 100. Control mice were treated with vehicle alone without CDDO-Me. In a separate group,
mice were also treated with gemcitabine i.p., twice a week at a dose of 2 mg/kg to compare the activity of CDDO-Me to that of a standard agent for PDAC.
Kaplan-Meier plots (F) represent survival data of vehicle only, gemcitabine or CDDO-Me treated animals.

was monitored non-invasively by bioluminescence imaging
using Kodak Multispectral Imaging System (Carestream
Health, Woodbridge, CT, USA). Fig. 5 shows BLI images of a
xenograft on days 15 and 35 (Fig. 5A and B) and a metastatic
lesion in the liver (Fig. 5B, arrow). The growth curve of xenografts was created by plotting photon flux emission (photons/
sec/mm2) from tumors at various time points past tumor cell
injection in the pancreas (Fig. 5C). The anatomical location of
tumors was visually confirmed upon opening the abdominal
cavity and tumors were harvested and identified as PDAC
histologically (Fig. 5D and E).
We used the orthotopic xenogaft model to generate residual
disease to investigate efficacy of CDDO-Me for preventing
relapse (recurrence) after surgical removal of tumors. In this
case, after injection of MiaPaCa-2-luc cells in the pancreatic
tail, tumor cells were first allowed to form tumors. On day 28,
tumors were resected to remove all of the visible tumor growth
in each animal. One day after removal of tumors, mice were
treated with vehicle alone (n=9) or CDDO-Me by oral gavage
at a dose of 15 µmol/kg as described in Materials and methods
(n=12). Separately, mice were also treated with gemcitabine,
the standard drug used for treating pancreatic cancer, at a
dose of 2 mg/kg, 2 times per week, i.p. (n=9). Experiment was
terminated on day 100 and survival data were compared.

As shown in Fig. 5F, six of the nine mice in the vehicle
control group died during this period (33% survival; mean
survival time =81.6±22 days). Five of the nine mice treated
with gemcitabine survived during the same period (56%
survival; mean survival time =81±25 days, p>0.05). However,
the group of mice treated with CDDO-Me showed the best
survival rate, i.e., eight of the 12 mice treated with CDDO-Me
revealed the presence of tumours in 2 of the 3 vehicle control, 2
of the 5 gemcitabine-treated and 1 of the 8 CDDO‑Me-treated
surviving mice on day 100.
Discussion
Pancreatic ductal adenocarcinoma is an intractable malignant disease with limited therapeutic options. Discovering
effective novel agents with defined therapeutic targets might
provide urgently needed therapeutics to treat this cancer.
Natural products have long been recognized as a rich source
of chemical diversity and compounds with a wide spectrum
of anticancer activities. From vincristine to paclitaxel, the
effective antitumor activity and novel mechanisms of action
of many natural compounds and their synthetic derivatives
have been described (22,23). CDDO and CDDO-Me are
synthetic triterpenoids derived from oleanolic acid with
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potent antiproliferative and pro-apoptotic activity. Earlier
we demonstrated efficacy of CDDO and CDDO-Me in
preventing/delaying the development and progression of prostate cancer in the transgenic TRAMP mouse model of prostate
tumorigenesis (24,25). Others have shown efficacy of CDDOs
for breast, lung and colon cancers (26,27). On the other hand,
therapeutic efficacy of CDDOs for pancreatic cancer has not
been adequately investigated. Studies described in this report
were intended to determine therapeutic efficacy of CDDO-Me
for pancreatic ductal adenocarcinoma. Since Kras is mutated
in >90% of human PDAC and mutation of Kras at codon
G12 leads to constitutive activation of Kras oncoprotein and
more aggressive PDAC phenotype (28), we investigated the
anticancer activity of CDDO-Me in vitro and in vivo using
two PDAC cell lines with and without activating K-ras mutations (MiaPaCa-2 and BxPC-3, respectively). CDDO-Me
strongly inhibited the proliferation of both cell lines in vitro
independent of K-ras mutations. Since inhibition of cell
proliferation induces apoptosis in cancer cells, we assessed
induction of apoptosis by CDDO-Me in PDAC cells. Induction
of apoptosis was measured by the binding of Annexin V-FITC
to phosphotidylserine which is externalized to the outer
leaflet of the plasma membrane early during induction of
apoptosis. Treatment with CDDO-Me significantly increased
the percentage of Annexin V-FITC binding cells in both cell
lines. Induction of apoptosis was confirmed by the cleavage of
PARP-1, a hallmark of cells undergoing apoptosis.
PI3K/Akt/mTOR and Akt/NF-кB are major antiapoptotic/
prosurvival signaling pathways that are constitutively active in
most cancers including pancreatic cancer. Akt promotes cell
growth and survival by inactivating downstream substrates
such as Bad, procaspase-9 and forkhead transcription factors
(28,29). Antiapoptotic NF-κ B and progrowth mTOR signaling
pathways are downstream targets of activated PI3K/AKT. The
NF-κ B family of transcription factors controls the expression
of genes involved in immune, inflammatory and oncogenic
responses and play a critical role in resistance of cancer cells
to anticancer therapies by protecting them from apoptosis
(30). mTOR is a serine-threonine kinase, which controls cell
growth, survival and ribogenesis (31). CDDO-Me inhibited
the expression of p-AKT, NF-κ B and p-mTOR in MiaPaCa-2
and BxPC-3 cells. The inhibition of these anti-apoptotic and
survival-promoting signaling proteins suggested that they are
involved in mediating the antiproliferative and proapoptotic
activity of CDDO-Me in PDAC cells.
The results of in vitro studies showing strong antiproliferative and proapoptotic activity of CDDO-Me for PDAC
cells prompted us to evaluate its therapeutic efficacy for
PDAC in vivo, since many times antitumor effects observed
in cell lines in vitro do not pan out in vivo. We first examined CDDO-Me for therapeutic efficacy against heterotopic
xenografts generated with BxPC-3 cells with normal K-ras
expression. Treatment with CDDO-Me significantly inhibited
the growth of heterotopic xenografts (p<0.01). Western blot
analysis of the tumor tissue extract showed that the inhibition
of tumor growth was associated with the inhibition of antiapoptotic/prosurvival p-Akt, NF-кB and p-mTOR signaling
proteins. These data also demonstrated that in vitro effects
of CDDO-Me in PDAC cells does translate into therapeutic
efficacy in vivo.
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To further analyze therapeutic efficacy of CDDO-Me for
PDAC, we tested it for preventing relapse/recurrence when
administered after surgical resection of tumors. This was
accomplished by creating a model of PDAC residual disease
wherein orthotopic PDAC xenografts generated by implanting
MiaPaCa-2-Luc cells in the pancreas were surgically removed
after four weeks of tumor growth. Treatment with CDDO-Me
in this adjuvant setting significantly prolonged survival of mice
compared to untreated animals. In fact, the survival advantage
with CDDO-Me was even better than that with gemcitabine,
a standard drug for the treatment of patients with advanced
PDAC. Thus, therapeutic outcomes in xenografts models
generated with PDAC cells expressing either normal K-ras
(BxPC-3) or activated K-ras (MiaPaCa-2) correlated with
responses to CDDO-Me in vitro. Although the exact mechanism of the antitumor activity of CDDO-Me in vivo remain to
be investigated, our data suggest that downregulation of p-Akt,
NF-кB and p-mTOR signaling proteins plays a role in inhibition of cell proliferation and induction of cellular apoptosis in
tumor cells by CDDO-Me. Since treatment with gemcitabine
or CDDO-Me alone improved survival when administered
after removal of tumors suggests that combinatorial regimen
of gemcitabine and CDDO-Me might be even more beneficial
in preventing/delaying recurrence. This inference of course
needs more rigorous analysis in these preclinical models of
PDAC.
In conclusion, our investigations show that CDDO-Me
exhibits therapeutic efficacy in xenograft models of PDAC
(heterotopic and orthotopic) for inhibiting primary tumor
growth and delaying/preventing relapse by destroying residual
disease. Because of its ability to inhibit p-AKT, NF-κ B and
p-mTOR in tumor tissue, we speculate that CDDO-Me inhibits
tumor growth by inhibiting cell proliferation and promoting
apoptosis through the inhibition of anti-apoptotic/prosurvival
AKT/NF-κ B/mTOR signaling pathways. Collectively, these
findings unveiling antitumor potential of CDDO-Me for PDAC
warrant further studies for development of CDDO-Me as an
adjuvant to existing PDAC therapies to obtain more durable
responses and improved outcomes.
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